Search PubMed⌕ Search

PubMed · 12352004

Autonomic neuropathies.

Abstract

PURPOSE OF REVIEW: To update recent advances in the pathogenesis, pathophysiology and treatment of some autonomic neuropathies. RECENT FINDINGS: When evaluating a patient with subacute autonomic neuropathy, certain autoantibodies are important in diagnosis and may influence management. Ganglionic antibody may be pathogenetically important while the paraneoplastic antibodies alert the clinician to the presence of an occult neoplasm. Autonomic failure is an integral component of diabetic neuropathy. Sildenafil is safe and efficacious in treating erectile dysfunction in diabetic patients. Sympathetic cardiac hyperinnervation can occur concurrently with denervation in diabetic neuropathy The gene mutations for hereditary sensory and autonomic neuropathies I, III, and IV are now known and there is clear unmyelinated fiber loss. Additional options for treatment of orthostatic hypotension include erythropoietin and, surprisingly, water. Botulinum toxin is efficacious, at least for a time, for the treatment of palmar and axillary hyperhidrosis. SUMMARY: Ganglionic antibody likely mediates autoimmune autonomic neuropathy. Sympathetic cardiac hyperinnervation can occur and could potentially cause arrhythmia and sudden death. Knowledge of gene mutations of hereditary sensory and autonomic neuropathies I, III and IV could lead to more secure diagnosis of the disorders. Effective treatment of essential hyperhidrosis with botulinum toxin injection has been demonstrated. It might be possible to improve treatment of orthostatic hypotension acutely with water imbibation and chronically with erythropoieting.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Phillip A Low. 2002. Autonomic neuropathies.. https://doi.org/10.1097/00019052-200210000-00011

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Intravenous immunoglobulin: striving for appropriate use.

BACKGROUND: Intravenous immunoglobulin (IVIG) is the mainstay therapy in human immune deficiency states characterized by qualitative and quantitative reductions in B cells. In addition, however, there is widespread use of IVIG in a number of other areas, including neuroimmunologic, infectious, dermatologic, hematologic, autoimmune, inflammatory and idiopathic disorders. In many of these cases, there are little objective data to support the use. METHODS: We performed a review of more than 400 publications in PubMed using the key words 'intravenous immunoglobulin' and excluded publications that focused on immune deficiency, for which the indication for IVIG is already clear. RESULTS: For a number of off-label indications, there is significant evidence of efficacy and IVIG has become the standard of care for many clinical syndromes other than immune deficiency. In some conditions, however, the data have not been well controlled or randomized and are often limited to case reports that are difficult to interpret. Although the critical shortage of IVIG of the last decade is no longer an issue, IVIG is expensive and not without risk. The use of IVIG should be based not only on clinical data, but also, and especially, on the biological rationale for its use. CONCLUSIONS: The appropriate use of IVIG is an important issue that is difficult to resolve, and will continue to challenge clinicians based on expense and potentially limited supply, including the intrinsic limitations of donor plasma. The establishment of national and international voluntary registries to report use of IVIG in disorders for which evidence is lacking would be a first step toward facilitating randomized, controlled clinical trials.

Autoimmune Diseases of the Nervous System↗

[Autoimmune epilepsy].

Explore the source record for details and available documents.

Autoimmune Diseases of the Nervous System↗